1 April 2021 - The April 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The April issue of the Schedule includes a few new/revised listings:

• Amino acid formula with vitamins and minerals without lysine and low in tryptophan (GA Gel, GA Express 15) - new indication
  
• Apomorphine hydrochloride monohydrate (Movapo PFS, Movapo) - restriction change
• Fulvestrant (Fulvestrant Sandoz) - new medicine
• Mometasone furoate with indacaterol maleate and glycopyrronium bromide (Enerzair Breezhaler) - new combination product
• Ribociclib succinate (Kisqali) - new indication
• Romosozumab (Evenity) - new medicine
• Secukinumab (Cosentyx) - new indication

Read Summary of Changes

Apparently several new biosimilars for adalimumab (Humira) have been listed on the PBS today. This is not noted in Summary of Changes (on-line version). Could it be an April Fool's Day joke?